Close menu




July 28th, 2021 | 10:14 CEST

Barrick Gold, Mineworx, TUI: Summertime is investment time

  • Investments
Photo credits: pixabay.com

Invest or consume? Given the difficult months many of us have had, it would be understandable to unwind now: sun, beach and sea beckon despite rising numbers. But it may also make sense to think more long-term in the face of rapid change. Central banks are allowing more inflation and the printing press continues to run fast. Especially in the current summer lethargy, this can be an opportunity for people with foresight.

time to read: 3 minutes | Author: Nico Popp
ISIN: BARRICK GOLD CORP. | CA0679011084 , MINEWORX TECHNOLOGIES LTD | CA6034652041 , TUI AG NA O.N. | DE000TUAG000

Table of contents:


    Barrick Gold: Truly the gold standard?

    Prices on the major stock exchanges are currently bobbing along. The gold price has consolidated after its rapid rise last year and shaken off some skeptics. This calm in the market is deceptive. Indices that track the volatility of the S&P 500 or other blue-chip barometers are trading at long-term lows. It appears that all it takes is a trigger to get the markets moving again. As a result, this is a good time to position oneself, adjust weightings in the portfolio and make strategic decisions, for example, for an investment in gold. Many private investors consider the shares of Barrick Gold to be the first port of call. It is understandable - after all, Barrick Gold is the world's second-largest gold producer.

    Recently, the stock picked up a bit and managed a return of 2.4% in just 5 days - for Barrick, this is almost a dynamic move. Previously, one had at times the impression that the stock was lagging the gold price a bit. Even during the most incredible euphoria in 2020, the share got going but could not maintain the level. Shareholders had the vain hope that Barrick would invest on a larger scale. To date, however, there has been no news on this. Barrick's stock is very solid and also offers a dividend. However, if you want to invest conservatively, you might be better off with an ETF on gold producers.

    Mineworx: Recycling makes the world a better place

    The situation is entirely different for the young Company Mineworx. Together with the US recycling specialist Davis Recycling, the Canadians want to extract platinum and palladium from diesel catalytic converters. A commercial plant is to be built for this purpose in the US state of Tennessee. Mineworx recently announced that it had completed a pilot plant. The plant is designed so that the Mineworx team can still fine-tune processes and techniques to further increase efficiency and secure even more of the valuable precious metals. The Company sees its business model as a great opportunity - currently, only about 30% of all catalysts are recycled. Together with its partner Davis Recycling, which has understood the business for twenty years, Mineworx wants to take off. "Now that we have successfully completed the construction of the pilot plant, we are looking forward to moving to the testing phase of the catalyst project. This is a big step for our Company as we work with our partner Davis Recycling to bring our technology to the commercial stage," commented Greg Pendura, President and CEO of Mineworx.

    The Canadians' second asset is a historic iron ore concession in southeastern Spain. Here Mineworx holds a 100% interest and suspects a high-grade resource of up to 42 million t. iron ore. An exploration program is planned and is expected to commence once permitting procedures have been completed. Mineworx's stock must be considered speculative. Recently, however, the value climbed upwards. There is currently around 100% clearance to the highs for the year. Given the early stage of the Company, positive news could also give the share new impetus. However, investors should add the stock to their well-thought-out asset allocation according to their own risk profile. If all goes well, Mineworx can benefit from the general development of commodity prices and their operational progress.

    TUI: Consumption instead of investment

    With most people in Germany thinking more about consuming than investing, investors may also find TUI's stock exciting. Since the group's rescue thanks to government aid, however, the share has at best been moving sideways with a slight upward trend. The renewed climb in incidences is a cause for concern. Recently, Spain and the Netherlands have also been classified as high-incidence areas. That makes it difficult for the unvaccinated in particular, as quarantine is required on their return. Currently, there are also discussions to restrict travel further and to introduce a general testing obligation. All measures are sensible from an epidemiological point of view, but they are poison for companies like TUI. Even the hope for an autumn season is no reason to invest in the share.


    While any bet on TUI currently seems ill-founded, an investment in a solid gold producer like Barrick can be a good choice. However, the stock is lagging in the overall market. Mineworx shares could offer a good combination of an investment in the commodities market and innovative recycling solutions. While investors should keep in mind that this is speculative, the opportunities are there.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read